| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Purpura, Thrombocytopenic, Idiopathic | 51 | 2024 | 242 | 17.970 |
Why?
|
| Thrombopoietin | 70 | 2024 | 226 | 16.190 |
Why?
|
| Receptors, Fc | 37 | 2024 | 537 | 10.470 |
Why?
|
| Thrombocytopenia | 52 | 2024 | 1182 | 9.190 |
Why?
|
| Recombinant Fusion Proteins | 38 | 2023 | 3726 | 6.560 |
Why?
|
| Receptors, Thrombopoietin | 31 | 2021 | 160 | 6.190 |
Why?
|
| Benzoates | 12 | 2020 | 211 | 3.450 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 9 | 2023 | 147 | 3.450 |
Why?
|
| Hydrazines | 12 | 2020 | 222 | 3.420 |
Why?
|
| Platelet Count | 43 | 2023 | 782 | 3.400 |
Why?
|
| Blood Platelets | 35 | 2023 | 2477 | 2.530 |
Why?
|
| Gaucher Disease | 7 | 2020 | 110 | 2.270 |
Why?
|
| Thrombopoiesis | 12 | 2021 | 164 | 2.260 |
Why?
|
| Hemin | 6 | 2015 | 51 | 1.990 |
Why?
|
| Telangiectasia, Hereditary Hemorrhagic | 5 | 2021 | 141 | 1.910 |
Why?
|
| Pyrazoles | 12 | 2020 | 2010 | 1.850 |
Why?
|
| Hematologic Agents | 3 | 2018 | 40 | 1.620 |
Why?
|
| Pregnancy Complications, Hematologic | 5 | 2024 | 180 | 1.570 |
Why?
|
| Megakaryocytes | 19 | 2014 | 566 | 1.280 |
Why?
|
| Antimalarials | 8 | 2017 | 907 | 1.130 |
Why?
|
| Receptors, Cytokine | 7 | 2001 | 257 | 1.110 |
Why?
|
| Hemorrhage | 11 | 2024 | 3422 | 1.060 |
Why?
|
| Anemia | 5 | 2024 | 1504 | 1.040 |
Why?
|
| Thiophenes | 6 | 2023 | 569 | 0.990 |
Why?
|
| Platelet Transfusion | 12 | 2022 | 298 | 0.940 |
Why?
|
| Splenectomy | 9 | 2022 | 391 | 0.920 |
Why?
|
| Hemoglobinuria, Paroxysmal | 2 | 2023 | 95 | 0.910 |
Why?
|
| Chloroquine | 2 | 2015 | 274 | 0.850 |
Why?
|
| Porphyria, Acute Intermittent | 2 | 2021 | 15 | 0.850 |
Why?
|
| Blood Preservation | 6 | 2018 | 169 | 0.820 |
Why?
|
| Polyethylene Glycols | 14 | 2011 | 1187 | 0.800 |
Why?
|
| Complement Inactivating Agents | 2 | 2023 | 53 | 0.790 |
Why?
|
| Morpholines | 2 | 2022 | 581 | 0.750 |
Why?
|
| Aminopyridines | 2 | 2022 | 573 | 0.710 |
Why?
|
| Thiazoles | 6 | 2023 | 1517 | 0.700 |
Why?
|
| Humans | 183 | 2024 | 761222 | 0.690 |
Why?
|
| Erythrocyte Transfusion | 3 | 2022 | 569 | 0.690 |
Why?
|
| Liver Diseases | 4 | 2021 | 1301 | 0.680 |
Why?
|
| Enzyme Replacement Therapy | 1 | 2020 | 80 | 0.670 |
Why?
|
| Anemia, Aplastic | 1 | 2021 | 230 | 0.660 |
Why?
|
| von Willebrand Disease, Type 1 | 1 | 2019 | 5 | 0.660 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2019 | 410 | 0.650 |
Why?
|
| Glucosylceramidase | 1 | 2020 | 126 | 0.650 |
Why?
|
| Protoporphyrins | 3 | 2015 | 168 | 0.650 |
Why?
|
| Carrier Proteins | 8 | 2023 | 4935 | 0.650 |
Why?
|
| Iron Overload | 1 | 2021 | 239 | 0.640 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2019 | 87 | 0.630 |
Why?
|
| Antineoplastic Agents | 14 | 2022 | 13632 | 0.620 |
Why?
|
| Blood Platelet Disorders | 1 | 2018 | 60 | 0.600 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2018 | 187 | 0.590 |
Why?
|
| Recombinant Proteins | 19 | 2014 | 6504 | 0.590 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2019 | 282 | 0.580 |
Why?
|
| Anticoagulants | 10 | 2018 | 4795 | 0.570 |
Why?
|
| Product Surveillance, Postmarketing | 3 | 2020 | 454 | 0.570 |
Why?
|
| Neoplasms | 16 | 2022 | 22142 | 0.560 |
Why?
|
| Adult | 67 | 2024 | 221120 | 0.550 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2019 | 305 | 0.550 |
Why?
|
| Autoimmunity | 3 | 2022 | 1356 | 0.540 |
Why?
|
| 1-Deoxynojirimycin | 2 | 2013 | 18 | 0.540 |
Why?
|
| Hematologic Neoplasms | 5 | 2022 | 1895 | 0.530 |
Why?
|
| Middle Aged | 66 | 2024 | 220858 | 0.530 |
Why?
|
| Heparin | 4 | 2017 | 1632 | 0.530 |
Why?
|
| Prothrombin | 3 | 2022 | 192 | 0.530 |
Why?
|
| Neoplasm Proteins | 9 | 2001 | 3594 | 0.530 |
Why?
|
| Hemangiosarcoma | 1 | 2018 | 215 | 0.530 |
Why?
|
| Bacterial Vaccines | 1 | 2018 | 399 | 0.530 |
Why?
|
| Hemeproteins | 5 | 2017 | 61 | 0.520 |
Why?
|
| Disease Susceptibility | 2 | 2019 | 1791 | 0.510 |
Why?
|
| Antiphospholipid Syndrome | 2 | 2014 | 165 | 0.500 |
Why?
|
| Antifibrinolytic Agents | 1 | 2018 | 287 | 0.490 |
Why?
|
| Molecular Dynamics Simulation | 2 | 2015 | 427 | 0.480 |
Why?
|
| Plateletpheresis | 6 | 2004 | 38 | 0.480 |
Why?
|
| Treatment Outcome | 28 | 2024 | 64681 | 0.480 |
Why?
|
| End Stage Liver Disease | 1 | 2019 | 352 | 0.470 |
Why?
|
| Pre-Eclampsia | 1 | 2024 | 1233 | 0.470 |
Why?
|
| Erythrocytes | 5 | 2022 | 2413 | 0.460 |
Why?
|
| Thrombosis | 7 | 2023 | 2944 | 0.460 |
Why?
|
| Aged | 48 | 2024 | 169292 | 0.460 |
Why?
|
| Complement C1s | 3 | 2023 | 11 | 0.460 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 3 | 2017 | 1651 | 0.450 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2014 | 694 | 0.440 |
Why?
|
| Antibodies, Neutralizing | 2 | 2020 | 1935 | 0.440 |
Why?
|
| Perioperative Care | 2 | 2018 | 1037 | 0.440 |
Why?
|
| Adrenal Cortex Hormones | 6 | 2022 | 1878 | 0.440 |
Why?
|
| Female | 72 | 2024 | 392552 | 0.430 |
Why?
|
| Male | 75 | 2024 | 360703 | 0.430 |
Why?
|
| Oxazolidinones | 3 | 2003 | 98 | 0.430 |
Why?
|
| Immunoglobulins, Intravenous | 4 | 2021 | 668 | 0.430 |
Why?
|
| Viral Vaccines | 1 | 2018 | 593 | 0.430 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 2 | 2020 | 131 | 0.420 |
Why?
|
| Immunoglobulin G | 3 | 2019 | 4537 | 0.420 |
Why?
|
| Reticulin | 2 | 2009 | 19 | 0.410 |
Why?
|
| Blood Donors | 5 | 2008 | 345 | 0.410 |
Why?
|
| Virus Diseases | 1 | 2018 | 716 | 0.400 |
Why?
|
| Venous Thrombosis | 7 | 2016 | 1304 | 0.400 |
Why?
|
| Pyrimidines | 2 | 2022 | 3027 | 0.400 |
Why?
|
| Acetamides | 3 | 2003 | 257 | 0.390 |
Why?
|
| Proto-Oncogene Proteins | 7 | 2001 | 4513 | 0.390 |
Why?
|
| Dose-Response Relationship, Drug | 12 | 2018 | 10756 | 0.380 |
Why?
|
| Hepatitis C | 1 | 2021 | 1579 | 0.380 |
Why?
|
| Dimerization | 4 | 2014 | 887 | 0.380 |
Why?
|
| Liver Transplantation | 2 | 2023 | 2332 | 0.370 |
Why?
|
| Combined Modality Therapy | 7 | 2021 | 8519 | 0.370 |
Why?
|
| Clinical Trials as Topic | 13 | 2021 | 8002 | 0.370 |
Why?
|
| Tungsten | 2 | 2021 | 19 | 0.370 |
Why?
|
| Hemoglobins | 7 | 2021 | 1525 | 0.360 |
Why?
|
| Nephelometry and Turbidimetry | 1 | 2010 | 91 | 0.360 |
Why?
|
| Dalteparin | 3 | 2012 | 44 | 0.360 |
Why?
|
| Immunoglobulin lambda-Chains | 1 | 2010 | 83 | 0.360 |
Why?
|
| Oxazines | 2 | 2023 | 349 | 0.360 |
Why?
|
| Bacterial Infections | 1 | 2018 | 1390 | 0.350 |
Why?
|
| Apoptosis | 6 | 2012 | 9478 | 0.350 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2010 | 170 | 0.350 |
Why?
|
| Aged, 80 and over | 20 | 2024 | 58952 | 0.340 |
Why?
|
| Quality of Life | 10 | 2023 | 13367 | 0.340 |
Why?
|
| Colony-Stimulating Factors | 4 | 2013 | 218 | 0.340 |
Why?
|
| Heparin, Low-Molecular-Weight | 2 | 2002 | 344 | 0.340 |
Why?
|
| Chronic Disease | 9 | 2024 | 9319 | 0.330 |
Why?
|
| Plasmodium falciparum | 4 | 2017 | 1740 | 0.330 |
Why?
|
| Thrombocythemia, Essential | 2 | 2020 | 113 | 0.330 |
Why?
|
| Hematology | 4 | 2019 | 243 | 0.320 |
Why?
|
| Thermodynamics | 4 | 2015 | 590 | 0.320 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2022 | 5665 | 0.320 |
Why?
|
| Liver Neoplasms | 5 | 2018 | 4310 | 0.310 |
Why?
|
| Postoperative Care | 1 | 2015 | 1468 | 0.310 |
Why?
|
| Hematopoietic Cell Growth Factors | 3 | 2008 | 98 | 0.310 |
Why?
|
| Disease Management | 6 | 2021 | 2507 | 0.310 |
Why?
|
| Leukemia | 1 | 2016 | 1518 | 0.310 |
Why?
|
| Blood Cell Count | 5 | 2019 | 396 | 0.310 |
Why?
|
| Retrospective Studies | 20 | 2023 | 80675 | 0.300 |
Why?
|
| Thrombin | 2 | 2012 | 593 | 0.300 |
Why?
|
| Young Adult | 18 | 2021 | 59222 | 0.300 |
Why?
|
| Autoantibodies | 5 | 2023 | 2119 | 0.300 |
Why?
|
| Polycythemia Vera | 2 | 2019 | 161 | 0.290 |
Why?
|
| Red-Cell Aplasia, Pure | 1 | 2007 | 27 | 0.290 |
Why?
|
| Hemolysis | 4 | 2023 | 415 | 0.290 |
Why?
|
| Quinolines | 1 | 2013 | 764 | 0.290 |
Why?
|
| Injections, Subcutaneous | 6 | 2013 | 672 | 0.280 |
Why?
|
| Blood Transfusion | 6 | 2021 | 1303 | 0.280 |
Why?
|
| Protozoan Proteins | 1 | 2013 | 846 | 0.280 |
Why?
|
| Double-Blind Method | 9 | 2023 | 12341 | 0.280 |
Why?
|
| Remission Induction | 3 | 2021 | 2392 | 0.280 |
Why?
|
| Anti-Infective Agents | 3 | 2003 | 983 | 0.270 |
Why?
|
| Self Administration | 2 | 2020 | 387 | 0.250 |
Why?
|
| Primary Myelofibrosis | 1 | 2007 | 208 | 0.250 |
Why?
|
| Pipecolic Acids | 1 | 2006 | 77 | 0.250 |
Why?
|
| Malaria, Falciparum | 2 | 2013 | 1076 | 0.250 |
Why?
|
| X-Ray Absorption Spectroscopy | 2 | 2015 | 5 | 0.250 |
Why?
|
| Ploidies | 6 | 1996 | 285 | 0.240 |
Why?
|
| Serum Albumin, Bovine | 2 | 2005 | 319 | 0.240 |
Why?
|
| Blood Coagulation | 3 | 2020 | 1156 | 0.240 |
Why?
|
| Databases, Factual | 1 | 2020 | 7965 | 0.230 |
Why?
|
| Time Factors | 15 | 2019 | 39957 | 0.230 |
Why?
|
| Registries | 1 | 2020 | 8246 | 0.220 |
Why?
|
| Pyridines | 3 | 2023 | 2872 | 0.220 |
Why?
|
| Bone Marrow Cells | 11 | 2014 | 2410 | 0.220 |
Why?
|
| Standard of Care | 2 | 2021 | 550 | 0.220 |
Why?
|
| Immunosuppressive Agents | 4 | 2022 | 4190 | 0.220 |
Why?
|
| Administration, Oral | 3 | 2022 | 4015 | 0.220 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 4 | 2019 | 5666 | 0.220 |
Why?
|
| Spectrophotometry, Ultraviolet | 2 | 2014 | 199 | 0.220 |
Why?
|
| Water | 3 | 2014 | 1410 | 0.210 |
Why?
|
| Quinidine | 2 | 2015 | 52 | 0.210 |
Why?
|
| Quinine | 2 | 2015 | 51 | 0.210 |
Why?
|
| Neutropenia | 5 | 2013 | 885 | 0.210 |
Why?
|
| Stem Cell Transplantation | 2 | 2009 | 1600 | 0.200 |
Why?
|
| Catheterization | 2 | 2005 | 1428 | 0.200 |
Why?
|
| Transplantation, Autologous | 1 | 2007 | 2112 | 0.200 |
Why?
|
| Catheterization, Central Venous | 2 | 2005 | 526 | 0.200 |
Why?
|
| Porphyrias, Hepatic | 1 | 2021 | 7 | 0.200 |
Why?
|
| Platelet Factor 4 | 4 | 2017 | 129 | 0.200 |
Why?
|
| Follow-Up Studies | 7 | 2022 | 39127 | 0.200 |
Why?
|
| Bone Marrow | 5 | 2010 | 2911 | 0.200 |
Why?
|
| Hematopoiesis | 5 | 2001 | 2049 | 0.200 |
Why?
|
| Stromal Cells | 1 | 2007 | 1329 | 0.200 |
Why?
|
| Aminoquinolines | 2 | 2013 | 106 | 0.200 |
Why?
|
| Neutrophils | 3 | 2012 | 3763 | 0.190 |
Why?
|
| Catheters, Indwelling | 1 | 2004 | 426 | 0.190 |
Why?
|
| Bone Marrow Diseases | 2 | 2013 | 233 | 0.190 |
Why?
|
| Risk Reduction Behavior | 1 | 2008 | 1111 | 0.190 |
Why?
|
| Complement C5 | 1 | 2021 | 104 | 0.190 |
Why?
|
| Rho(D) Immune Globulin | 1 | 2020 | 34 | 0.180 |
Why?
|
| Urate Oxidase | 1 | 2020 | 31 | 0.180 |
Why?
|
| Plaque, Atherosclerotic | 2 | 2022 | 1535 | 0.180 |
Why?
|
| Methemoglobinemia | 1 | 2020 | 44 | 0.180 |
Why?
|
| Glycogen Storage Disease Type I | 1 | 2020 | 53 | 0.180 |
Why?
|
| Drug Resistance | 2 | 2020 | 1594 | 0.180 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2017 | 3803 | 0.180 |
Why?
|
| Medication Errors | 1 | 2006 | 783 | 0.170 |
Why?
|
| Drug Tolerance | 1 | 2021 | 367 | 0.160 |
Why?
|
| Decision Trees | 2 | 2019 | 505 | 0.160 |
Why?
|
| Blood Coagulation Tests | 2 | 2019 | 271 | 0.160 |
Why?
|
| Blood Component Transfusion | 2 | 2013 | 142 | 0.160 |
Why?
|
| Platelet Glycoprotein GPIb-IX Complex | 1 | 2020 | 144 | 0.160 |
Why?
|
| Severity of Illness Index | 5 | 2021 | 15841 | 0.160 |
Why?
|
| Ristocetin | 1 | 2018 | 26 | 0.160 |
Why?
|
| Spectrometry, X-Ray Emission | 1 | 2019 | 143 | 0.160 |
Why?
|
| Abruptio Placentae | 1 | 2020 | 118 | 0.160 |
Why?
|
| Spectrophotometry | 3 | 2018 | 292 | 0.160 |
Why?
|
| Busulfan | 5 | 1999 | 258 | 0.160 |
Why?
|
| Hyperammonemia | 1 | 2020 | 76 | 0.160 |
Why?
|
| Normal Distribution | 1 | 2019 | 272 | 0.160 |
Why?
|
| Early Diagnosis | 2 | 2020 | 1186 | 0.150 |
Why?
|
| Skin Diseases | 1 | 2007 | 1095 | 0.150 |
Why?
|
| Living Donors | 2 | 2023 | 643 | 0.150 |
Why?
|
| Drug Substitution | 1 | 2021 | 291 | 0.150 |
Why?
|
| Hydroxyurea | 1 | 2019 | 284 | 0.150 |
Why?
|
| Ferritins | 1 | 2021 | 596 | 0.150 |
Why?
|
| Animals | 34 | 2021 | 168089 | 0.150 |
Why?
|
| Antigens, CD34 | 1 | 2000 | 655 | 0.150 |
Why?
|
| Drug Administration Schedule | 4 | 2018 | 4851 | 0.150 |
Why?
|
| Pyruvate Metabolism, Inborn Errors | 1 | 2018 | 49 | 0.150 |
Why?
|
| Adenosine Diphosphate | 1 | 2018 | 422 | 0.150 |
Why?
|
| Anemia, Hemolytic, Congenital Nonspherocytic | 1 | 2018 | 55 | 0.140 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2000 | 617 | 0.140 |
Why?
|
| Infusions, Intravenous | 2 | 2018 | 2217 | 0.140 |
Why?
|
| Quality Assurance, Health Care | 1 | 2008 | 2164 | 0.140 |
Why?
|
| Patient Compliance | 1 | 2008 | 2688 | 0.140 |
Why?
|
| Hematologic Diseases | 1 | 2001 | 496 | 0.140 |
Why?
|
| Hydrogen Bonding | 2 | 2015 | 289 | 0.140 |
Why?
|
| ROC Curve | 3 | 2020 | 3584 | 0.140 |
Why?
|
| Arachidonic Acid | 1 | 2018 | 427 | 0.140 |
Why?
|
| Pyruvate Kinase | 1 | 2018 | 189 | 0.140 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 1998 | 223 | 0.140 |
Why?
|
| Live Birth | 1 | 2020 | 511 | 0.140 |
Why?
|
| Sensitivity and Specificity | 5 | 2020 | 14675 | 0.140 |
Why?
|
| Arteriovenous Malformations | 1 | 2020 | 396 | 0.140 |
Why?
|
| Platelet Aggregation | 2 | 2018 | 771 | 0.140 |
Why?
|
| Temperature | 1 | 2003 | 2219 | 0.130 |
Why?
|
| Blood Coagulation Factors | 1 | 2019 | 366 | 0.130 |
Why?
|
| Watchful Waiting | 1 | 2020 | 489 | 0.130 |
Why?
|
| Models, Biological | 6 | 2020 | 9458 | 0.130 |
Why?
|
| Lipoproteins | 1 | 2001 | 877 | 0.130 |
Why?
|
| Hemostatics | 1 | 2019 | 240 | 0.130 |
Why?
|
| Genes, Dominant | 1 | 2019 | 850 | 0.130 |
Why?
|
| Thrombophilia | 1 | 2018 | 306 | 0.130 |
Why?
|
| Mefloquine | 1 | 2015 | 55 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2021 | 10218 | 0.130 |
Why?
|
| Models, Chemical | 2 | 2009 | 609 | 0.130 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2011 | 3610 | 0.130 |
Why?
|
| Jehovah's Witnesses | 1 | 2015 | 13 | 0.130 |
Why?
|
| Acetonitriles | 1 | 2015 | 54 | 0.130 |
Why?
|
| Multicenter Studies as Topic | 1 | 2020 | 1702 | 0.130 |
Why?
|
| Zinc | 1 | 2019 | 672 | 0.130 |
Why?
|
| Solutions | 2 | 2014 | 410 | 0.130 |
Why?
|
| Abortion, Spontaneous | 1 | 2020 | 533 | 0.120 |
Why?
|
| Lasers | 1 | 2019 | 952 | 0.120 |
Why?
|
| Consensus | 2 | 2019 | 3134 | 0.120 |
Why?
|
| Delphi Technique | 1 | 2019 | 848 | 0.120 |
Why?
|
| Epinephrine | 1 | 2018 | 791 | 0.120 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2018 | 664 | 0.120 |
Why?
|
| von Willebrand Factor | 1 | 2019 | 677 | 0.120 |
Why?
|
| Coordination Complexes | 1 | 2015 | 73 | 0.120 |
Why?
|
| Antibodies | 2 | 2006 | 2415 | 0.120 |
Why?
|
| Growth Substances | 2 | 1994 | 759 | 0.120 |
Why?
|
| Siblings | 1 | 2019 | 824 | 0.120 |
Why?
|
| Rats | 15 | 2009 | 23705 | 0.120 |
Why?
|
| Caspases | 3 | 2003 | 878 | 0.110 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 4 | 2009 | 890 | 0.110 |
Why?
|
| Adolescent | 9 | 2020 | 88300 | 0.110 |
Why?
|
| Receptors, Immunologic | 1 | 2000 | 1408 | 0.110 |
Why?
|
| Molecular Conformation | 1 | 2015 | 543 | 0.110 |
Why?
|
| Physicians | 3 | 2019 | 4584 | 0.110 |
Why?
|
| Signal Transduction | 3 | 2013 | 23419 | 0.110 |
Why?
|
| IgA Deficiency | 1 | 2013 | 39 | 0.110 |
Why?
|
| Ferric Compounds | 1 | 2015 | 378 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 3 | 2021 | 9187 | 0.110 |
Why?
|
| Venous Thromboembolism | 3 | 2020 | 1869 | 0.110 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2019 | 1348 | 0.110 |
Why?
|
| Protein Conformation | 1 | 2021 | 3933 | 0.110 |
Why?
|
| Crotalid Venoms | 1 | 1992 | 28 | 0.100 |
Why?
|
| Rosette Formation | 1 | 2012 | 152 | 0.100 |
Why?
|
| Myeloid Cells | 1 | 2017 | 822 | 0.100 |
Why?
|
| Molecular Structure | 2 | 2014 | 1875 | 0.100 |
Why?
|
| Solubility | 1 | 2014 | 1085 | 0.100 |
Why?
|
| Coronary Artery Disease | 2 | 2022 | 6506 | 0.100 |
Why?
|
| Fetal Blood | 1 | 2019 | 1348 | 0.100 |
Why?
|
| Spectrophotometry, Infrared | 1 | 2012 | 117 | 0.100 |
Why?
|
| Fibrinolytic Agents | 1 | 2002 | 2075 | 0.100 |
Why?
|
| Quantum Theory | 1 | 2012 | 69 | 0.100 |
Why?
|
| Fever | 2 | 2011 | 1618 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 3 | 2020 | 7400 | 0.100 |
Why?
|
| Boronic Acids | 2 | 2009 | 915 | 0.100 |
Why?
|
| Thromboembolism | 1 | 1999 | 992 | 0.100 |
Why?
|
| Preoperative Care | 1 | 2021 | 2241 | 0.100 |
Why?
|
| Drug Evaluation | 1 | 2013 | 641 | 0.100 |
Why?
|
| Up-Regulation | 1 | 2021 | 4111 | 0.100 |
Why?
|
| Pregnancy | 5 | 2024 | 29893 | 0.100 |
Why?
|
| Diffusion | 1 | 2014 | 813 | 0.100 |
Why?
|
| Gelsolin | 2 | 2003 | 189 | 0.090 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 3 | 2009 | 629 | 0.090 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2018 | 1116 | 0.090 |
Why?
|
| Half-Life | 2 | 2010 | 649 | 0.090 |
Why?
|
| Ferrous Compounds | 1 | 2011 | 41 | 0.090 |
Why?
|
| Bence Jones Protein | 1 | 2010 | 18 | 0.090 |
Why?
|
| Blood Protein Electrophoresis | 1 | 2010 | 65 | 0.090 |
Why?
|
| Hepatomegaly | 1 | 2010 | 84 | 0.090 |
Why?
|
| Myeloma Proteins | 1 | 2010 | 71 | 0.090 |
Why?
|
| Multiple Myeloma | 3 | 2020 | 5145 | 0.090 |
Why?
|
| Patients | 1 | 2017 | 906 | 0.090 |
Why?
|
| Molecular Mimicry | 1 | 2011 | 213 | 0.090 |
Why?
|
| Pyrazines | 2 | 2009 | 1202 | 0.090 |
Why?
|
| Densitometry | 1 | 2010 | 151 | 0.090 |
Why?
|
| Fatigue | 4 | 2022 | 1550 | 0.090 |
Why?
|
| Deoxycytidine | 1 | 2015 | 878 | 0.090 |
Why?
|
| Secondary Prevention | 3 | 2007 | 1472 | 0.090 |
Why?
|
| Collagen | 1 | 2018 | 2635 | 0.090 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2012 | 225 | 0.090 |
Why?
|
| History, 20th Century | 2 | 2014 | 2765 | 0.080 |
Why?
|
| Hemophilia A | 1 | 2013 | 359 | 0.080 |
Why?
|
| Quinacrine | 1 | 2009 | 24 | 0.080 |
Why?
|
| Caspase 3 | 2 | 2003 | 730 | 0.080 |
Why?
|
| Necrosis | 2 | 2007 | 1610 | 0.080 |
Why?
|
| Adenocarcinoma | 1 | 2007 | 6341 | 0.080 |
Why?
|
| Intention to Treat Analysis | 1 | 2010 | 413 | 0.080 |
Why?
|
| Hematopoietic Stem Cells | 3 | 2000 | 3390 | 0.080 |
Why?
|
| Erythropoietin | 4 | 2001 | 719 | 0.080 |
Why?
|
| Homocysteine | 2 | 2022 | 637 | 0.080 |
Why?
|
| Serum | 1 | 2010 | 208 | 0.080 |
Why?
|
| Oxygen | 3 | 2020 | 4228 | 0.080 |
Why?
|
| Bone and Bones | 1 | 2019 | 2568 | 0.080 |
Why?
|
| Fibrinogen | 2 | 2022 | 888 | 0.080 |
Why?
|
| Cisplatin | 1 | 2015 | 1652 | 0.080 |
Why?
|
| Anthelmintics | 1 | 2009 | 83 | 0.080 |
Why?
|
| Dengue | 1 | 2012 | 254 | 0.080 |
Why?
|
| Oligosaccharides | 1 | 2011 | 406 | 0.080 |
Why?
|
| Genetic Association Studies | 1 | 2018 | 2731 | 0.080 |
Why?
|
| Cell Survival | 4 | 2004 | 5778 | 0.080 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 2576 | 0.080 |
Why?
|
| Drug Design | 2 | 2007 | 1044 | 0.080 |
Why?
|
| Growth Inhibitors | 1 | 1990 | 374 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 2008 | 127 | 0.080 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2018 | 2047 | 0.080 |
Why?
|
| Biomimetics | 1 | 2009 | 171 | 0.080 |
Why?
|
| Kinetics | 3 | 2017 | 6312 | 0.080 |
Why?
|
| Kazakhstan | 1 | 2008 | 19 | 0.080 |
Why?
|
| Schistosoma mansoni | 1 | 2009 | 156 | 0.080 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 2 | 2020 | 425 | 0.080 |
Why?
|
| Recurrence | 3 | 2019 | 8457 | 0.080 |
Why?
|
| Models, Molecular | 3 | 2013 | 5406 | 0.070 |
Why?
|
| Liver | 3 | 2023 | 7512 | 0.070 |
Why?
|
| Paraproteinemias | 1 | 2010 | 250 | 0.070 |
Why?
|
| Peptide Fragments | 1 | 2020 | 5103 | 0.070 |
Why?
|
| Infant, Newborn | 2 | 2021 | 26200 | 0.070 |
Why?
|
| Hypertension | 1 | 2008 | 8536 | 0.070 |
Why?
|
| Pain | 2 | 2021 | 5072 | 0.070 |
Why?
|
| Cell Separation | 2 | 1992 | 1721 | 0.070 |
Why?
|
| Liver Cirrhosis | 1 | 2018 | 1932 | 0.070 |
Why?
|
| ADAM Proteins | 1 | 2009 | 238 | 0.070 |
Why?
|
| Membrane Transport Proteins | 1 | 2013 | 1031 | 0.070 |
Why?
|
| Janus Kinase 2 | 1 | 2010 | 559 | 0.070 |
Why?
|
| Organometallic Compounds | 1 | 2011 | 647 | 0.070 |
Why?
|
| Protein Biosynthesis | 1 | 1994 | 2091 | 0.070 |
Why?
|
| Evidence-Based Medicine | 2 | 2018 | 3691 | 0.070 |
Why?
|
| Transforming Growth Factor beta | 2 | 1992 | 1963 | 0.070 |
Why?
|
| Enzyme Activation | 3 | 2003 | 3577 | 0.070 |
Why?
|
| Glycoproteins | 1 | 1994 | 2203 | 0.070 |
Why?
|
| Salvage Therapy | 1 | 2013 | 1264 | 0.070 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2011 | 1393 | 0.070 |
Why?
|
| Medical History Taking | 1 | 2010 | 773 | 0.070 |
Why?
|
| Anesthesia, Conduction | 1 | 2010 | 262 | 0.070 |
Why?
|
| Interleukin-6 | 3 | 2022 | 3210 | 0.070 |
Why?
|
| Predictive Value of Tests | 2 | 2022 | 15308 | 0.070 |
Why?
|
| Benzimidazoles | 1 | 2011 | 858 | 0.070 |
Why?
|
| Protein Binding | 3 | 2010 | 9297 | 0.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2018 | 11733 | 0.070 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2018 | 2293 | 0.060 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2007 | 274 | 0.060 |
Why?
|
| Acute Disease | 1 | 2016 | 7226 | 0.060 |
Why?
|
| Peptides | 2 | 2009 | 4353 | 0.060 |
Why?
|
| Genetic Testing | 1 | 2019 | 3537 | 0.060 |
Why?
|
| Mortality | 1 | 2017 | 2896 | 0.060 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2009 | 709 | 0.060 |
Why?
|
| Heart Valve Diseases | 1 | 2013 | 1031 | 0.060 |
Why?
|
| Prospective Studies | 6 | 2021 | 54437 | 0.060 |
Why?
|
| N-Acetylneuraminic Acid | 2 | 2023 | 174 | 0.060 |
Why?
|
| Rabbits | 4 | 1996 | 4750 | 0.060 |
Why?
|
| Intraoperative Complications | 1 | 2012 | 1164 | 0.060 |
Why?
|
| Lung Neoplasms | 2 | 2007 | 13386 | 0.060 |
Why?
|
| Probability | 1 | 2010 | 2478 | 0.060 |
Why?
|
| Cells, Cultured | 8 | 2000 | 18927 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2003 | 1404 | 0.060 |
Why?
|
| Inflammation | 2 | 2022 | 10759 | 0.060 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 2 | 2013 | 225 | 0.060 |
Why?
|
| Cytochalasin B | 1 | 2004 | 74 | 0.060 |
Why?
|
| Radioimmunoassay | 1 | 2005 | 862 | 0.060 |
Why?
|
| Treatment Failure | 1 | 2010 | 2643 | 0.060 |
Why?
|
| Egtazic Acid | 1 | 2004 | 166 | 0.060 |
Why?
|
| Myeloproliferative Disorders | 1 | 2010 | 609 | 0.060 |
Why?
|
| Protease Inhibitors | 2 | 2009 | 752 | 0.060 |
Why?
|
| Ultrasonography, Interventional | 2 | 2022 | 1496 | 0.060 |
Why?
|
| Mutation | 2 | 2019 | 30004 | 0.060 |
Why?
|
| History, 17th Century | 1 | 2004 | 108 | 0.060 |
Why?
|
| Caspase 2 | 1 | 2003 | 26 | 0.060 |
Why?
|
| Logistic Models | 1 | 2018 | 13249 | 0.060 |
Why?
|
| Patient Selection | 2 | 2013 | 4246 | 0.060 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2014 | 3770 | 0.050 |
Why?
|
| Tissue Adhesives | 1 | 2005 | 173 | 0.050 |
Why?
|
| Prognosis | 3 | 2021 | 29688 | 0.050 |
Why?
|
| Bupropion | 1 | 2005 | 304 | 0.050 |
Why?
|
| Postoperative Complications | 3 | 2018 | 15637 | 0.050 |
Why?
|
| Complement Pathway, Classical | 1 | 2023 | 91 | 0.050 |
Why?
|
| Aortic Valve | 1 | 2013 | 1959 | 0.050 |
Why?
|
| Caspase 9 | 1 | 2003 | 184 | 0.050 |
Why?
|
| Neuraminidase | 1 | 2023 | 195 | 0.050 |
Why?
|
| Amyloidosis | 1 | 2010 | 865 | 0.050 |
Why?
|
| Thrombocytosis | 2 | 1996 | 88 | 0.050 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2013 | 1555 | 0.050 |
Why?
|
| Gastrointestinal Diseases | 1 | 2011 | 1201 | 0.050 |
Why?
|
| Endothelium, Vascular | 2 | 2009 | 4420 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3093 | 0.050 |
Why?
|
| Prevalence | 1 | 2019 | 15721 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2005 | 628 | 0.050 |
Why?
|
| Safety | 3 | 2001 | 1151 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3215 | 0.050 |
Why?
|
| Plasma | 1 | 2006 | 586 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 12474 | 0.050 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2005 | 489 | 0.050 |
Why?
|
| Glycomics | 1 | 2023 | 113 | 0.050 |
Why?
|
| Arginine | 1 | 2006 | 920 | 0.050 |
Why?
|
| Ribosomes | 2 | 1976 | 494 | 0.050 |
Why?
|
| Blood Loss, Surgical | 2 | 2018 | 637 | 0.050 |
Why?
|
| Acetylgalactosamine | 1 | 2021 | 39 | 0.050 |
Why?
|
| Fat Substitutes | 1 | 2001 | 4 | 0.050 |
Why?
|
| bcl-X Protein | 1 | 2003 | 410 | 0.050 |
Why?
|
| Donor Selection | 1 | 2023 | 232 | 0.050 |
Why?
|
| Iodine Radioisotopes | 1 | 2005 | 1030 | 0.050 |
Why?
|
| Food Additives | 1 | 2001 | 23 | 0.050 |
Why?
|
| Child, Preschool | 3 | 2018 | 42225 | 0.050 |
Why?
|
| Glucocorticoids | 1 | 2010 | 2159 | 0.050 |
Why?
|
| Coronary Vessels | 2 | 2022 | 3111 | 0.050 |
Why?
|
| Complement C3 | 1 | 2023 | 434 | 0.050 |
Why?
|
| Pneumonia, Bacterial | 1 | 2003 | 316 | 0.040 |
Why?
|
| Flow Cytometry | 4 | 2000 | 5871 | 0.040 |
Why?
|
| Cattle | 2 | 2005 | 3818 | 0.040 |
Why?
|
| Coronary Angiography | 2 | 2022 | 4507 | 0.040 |
Why?
|
| Reference Values | 2 | 2018 | 4921 | 0.040 |
Why?
|
| Hemostasis | 1 | 2023 | 470 | 0.040 |
Why?
|
| Blood Proteins | 2 | 2009 | 1173 | 0.040 |
Why?
|
| Sucrose | 1 | 2001 | 158 | 0.040 |
Why?
|
| Vancomycin | 1 | 2003 | 503 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 4 | 1997 | 8164 | 0.040 |
Why?
|
| Phenotype | 1 | 2018 | 16575 | 0.040 |
Why?
|
| Premedication | 2 | 2013 | 246 | 0.040 |
Why?
|
| Bile Acids and Salts | 1 | 2022 | 394 | 0.040 |
Why?
|
| Digestive System | 1 | 2001 | 244 | 0.040 |
Why?
|
| Headache | 2 | 2014 | 1255 | 0.040 |
Why?
|
| Receptors, Colony-Stimulating Factor | 1 | 2000 | 50 | 0.040 |
Why?
|
| Culture Media | 2 | 1994 | 894 | 0.040 |
Why?
|
| Leukemia, Erythroblastic, Acute | 2 | 2006 | 176 | 0.040 |
Why?
|
| Synchrotrons | 1 | 2019 | 39 | 0.040 |
Why?
|
| Multienzyme Complexes | 1 | 2003 | 665 | 0.040 |
Why?
|
| Pyrrolidines | 1 | 2021 | 339 | 0.040 |
Why?
|
| C-Reactive Protein | 2 | 2022 | 3821 | 0.040 |
Why?
|
| Platelet Function Tests | 1 | 2001 | 271 | 0.040 |
Why?
|
| Biopsy | 2 | 2010 | 6781 | 0.040 |
Why?
|
| Anesthesiology | 1 | 2010 | 1122 | 0.040 |
Why?
|
| Plasma Exchange | 1 | 2020 | 159 | 0.040 |
Why?
|
| Molecular Weight | 1 | 2001 | 2171 | 0.040 |
Why?
|
| Warfarin | 2 | 2004 | 1482 | 0.040 |
Why?
|
| Tomography, Optical Coherence | 2 | 2022 | 2923 | 0.040 |
Why?
|
| Pulmonary Embolism | 2 | 2016 | 2571 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2023 | 858 | 0.040 |
Why?
|
| Child | 5 | 2018 | 80154 | 0.040 |
Why?
|
| Interleukin-11 | 1 | 1999 | 58 | 0.040 |
Why?
|
| Cyclosporine | 1 | 2001 | 776 | 0.040 |
Why?
|
| Ammonia | 1 | 2020 | 243 | 0.040 |
Why?
|
| Umbilical Veins | 1 | 1999 | 423 | 0.040 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2001 | 342 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2010 | 3571 | 0.040 |
Why?
|
| Polypharmacy | 1 | 2001 | 307 | 0.040 |
Why?
|
| Kidney Function Tests | 1 | 2020 | 680 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2022 | 1032 | 0.040 |
Why?
|
| Blood Banks | 1 | 1999 | 108 | 0.040 |
Why?
|
| Risk Factors | 7 | 2022 | 74241 | 0.040 |
Why?
|
| Aspartate Aminotransferases | 1 | 2020 | 411 | 0.040 |
Why?
|
| Hemostasis, Surgical | 1 | 2018 | 126 | 0.040 |
Why?
|
| Pneumonectomy | 1 | 2005 | 1118 | 0.040 |
Why?
|
| Costs and Cost Analysis | 1 | 2004 | 1664 | 0.040 |
Why?
|
| Reticulocytes | 1 | 2018 | 288 | 0.040 |
Why?
|
| Methionine | 1 | 2000 | 570 | 0.040 |
Why?
|
| Enzyme Inhibitors | 2 | 2011 | 3702 | 0.040 |
Why?
|
| Hypercalcemia | 1 | 2020 | 423 | 0.040 |
Why?
|
| Transplantation Immunology | 1 | 2000 | 537 | 0.040 |
Why?
|
| False Negative Reactions | 1 | 2018 | 573 | 0.040 |
Why?
|
| Proteoglycans | 1 | 2000 | 803 | 0.040 |
Why?
|
| Art | 1 | 1998 | 64 | 0.040 |
Why?
|
| Gene Expression | 3 | 2000 | 7571 | 0.040 |
Why?
|
| RNA, Messenger | 4 | 2000 | 12747 | 0.040 |
Why?
|
| Alanine Transaminase | 1 | 2020 | 602 | 0.030 |
Why?
|
| Macrophages | 1 | 2012 | 5755 | 0.030 |
Why?
|
| Prednisone | 1 | 2001 | 1565 | 0.030 |
Why?
|
| Creatinine | 1 | 2022 | 1897 | 0.030 |
Why?
|
| Tissue Donors | 1 | 2006 | 2335 | 0.030 |
Why?
|
| Polysaccharides | 1 | 2023 | 1014 | 0.030 |
Why?
|
| Alkaline Phosphatase | 1 | 2020 | 859 | 0.030 |
Why?
|
| Cell Division | 3 | 1994 | 4451 | 0.030 |
Why?
|
| Structure-Activity Relationship | 2 | 2013 | 3057 | 0.030 |
Why?
|
| Transfection | 3 | 2000 | 5748 | 0.030 |
Why?
|
| Mitochondrial Proteins | 1 | 2002 | 974 | 0.030 |
Why?
|
| Postthrombotic Syndrome | 1 | 2016 | 28 | 0.030 |
Why?
|
| Primates | 1 | 1999 | 521 | 0.030 |
Why?
|
| Crystallization | 1 | 2017 | 528 | 0.030 |
Why?
|
| Protein Engineering | 1 | 2000 | 546 | 0.030 |
Why?
|
| Ligands | 1 | 2023 | 3264 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 2018 | 958 | 0.030 |
Why?
|
| Cell Nucleolus | 1 | 1976 | 153 | 0.030 |
Why?
|
| Cinchona Alkaloids | 1 | 2015 | 1 | 0.030 |
Why?
|
| Sulfonamides | 1 | 2006 | 1977 | 0.030 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 1997 | 326 | 0.030 |
Why?
|
| Cholesterol, HDL | 1 | 2022 | 1812 | 0.030 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2000 | 2478 | 0.030 |
Why?
|
| Mitosis | 2 | 1992 | 1187 | 0.030 |
Why?
|
| History, 19th Century | 1 | 1998 | 718 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2001 | 2082 | 0.030 |
Why?
|
| Tunica Intima | 1 | 1997 | 458 | 0.030 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 1999 | 617 | 0.030 |
Why?
|
| Epitopes | 1 | 2001 | 2504 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 2000 | 1087 | 0.030 |
Why?
|
| GPI-Linked Proteins | 2 | 1994 | 470 | 0.030 |
Why?
|
| X-Ray Diffraction | 1 | 2015 | 418 | 0.030 |
Why?
|
| Cloning, Molecular | 1 | 2000 | 4167 | 0.030 |
Why?
|
| Leukopenia | 1 | 1995 | 213 | 0.030 |
Why?
|
| Goats | 1 | 1994 | 165 | 0.030 |
Why?
|
| Cell Death | 1 | 2000 | 1676 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2008 | 8642 | 0.030 |
Why?
|
| Proteins | 4 | 1994 | 5993 | 0.030 |
Why?
|
| Ribosomal Proteins | 1 | 1976 | 370 | 0.030 |
Why?
|
| Immune Sera | 1 | 1994 | 605 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 2020 | 1302 | 0.030 |
Why?
|
| Phagocytosis | 1 | 2000 | 1525 | 0.030 |
Why?
|
| Fibrosis | 1 | 2021 | 2052 | 0.030 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2023 | 1892 | 0.030 |
Why?
|
| Cytokines | 2 | 2021 | 7386 | 0.030 |
Why?
|
| Smoking Cessation | 1 | 2005 | 2056 | 0.030 |
Why?
|
| Erythropoiesis | 2 | 2001 | 683 | 0.030 |
Why?
|
| Epistaxis | 1 | 2014 | 112 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2019 | 1567 | 0.030 |
Why?
|
| United States | 6 | 2019 | 72341 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2000 | 4567 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2000 | 1838 | 0.030 |
Why?
|
| Delayed Diagnosis | 1 | 2017 | 465 | 0.030 |
Why?
|
| Hemagglutination | 1 | 1992 | 32 | 0.030 |
Why?
|
| Fatty Acids | 1 | 2001 | 1807 | 0.030 |
Why?
|
| Intermittent Pneumatic Compression Devices | 1 | 2012 | 28 | 0.030 |
Why?
|
| Medical Oncology | 2 | 2017 | 2320 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2019 | 2189 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 20118 | 0.030 |
Why?
|
| Drugs, Investigational | 1 | 2014 | 212 | 0.020 |
Why?
|
| Antithrombin Proteins | 1 | 2011 | 10 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2021 | 22128 | 0.020 |
Why?
|
| Sheep | 1 | 1994 | 1436 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 2013 | 11476 | 0.020 |
Why?
|
| Sulfuric Acids | 1 | 1971 | 36 | 0.020 |
Why?
|
| Cesarean Section | 1 | 2020 | 1399 | 0.020 |
Why?
|
| Ruthenium | 1 | 2011 | 18 | 0.020 |
Why?
|
| Transcription, Genetic | 3 | 1995 | 7571 | 0.020 |
Why?
|
| Protein Denaturation | 1 | 1971 | 241 | 0.020 |
Why?
|
| Primary Health Care | 1 | 2008 | 4679 | 0.020 |
Why?
|
| Binding Sites | 2 | 2011 | 5988 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2000 | 6345 | 0.020 |
Why?
|
| Economics, Pharmaceutical | 1 | 2011 | 87 | 0.020 |
Why?
|
| Hydroxyl Radical | 1 | 2011 | 82 | 0.020 |
Why?
|
| Infant | 1 | 2013 | 36170 | 0.020 |
Why?
|
| Placenta | 1 | 2020 | 1711 | 0.020 |
Why?
|
| Perioperative Period | 1 | 2012 | 252 | 0.020 |
Why?
|
| Detergents | 1 | 1971 | 235 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2009 | 9278 | 0.020 |
Why?
|
| Electrochemistry | 1 | 2011 | 145 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2023 | 3048 | 0.020 |
Why?
|
| Sleep Disorders, Intrinsic | 1 | 2010 | 16 | 0.020 |
Why?
|
| Hemorrhagic Disorders | 1 | 2010 | 34 | 0.020 |
Why?
|
| Hospitalization | 2 | 2020 | 10707 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 4107 | 0.020 |
Why?
|
| Carotid Stenosis | 1 | 1997 | 859 | 0.020 |
Why?
|
| Artifacts | 1 | 2018 | 1912 | 0.020 |
Why?
|
| Algorithms | 1 | 2010 | 14025 | 0.020 |
Why?
|
| Stereoisomerism | 1 | 2011 | 611 | 0.020 |
Why?
|
| Forecasting | 1 | 1999 | 2928 | 0.020 |
Why?
|
| Parasite Egg Count | 1 | 2009 | 29 | 0.020 |
Why?
|
| Inpatients | 1 | 2001 | 2545 | 0.020 |
Why?
|
| Cohort Studies | 3 | 2021 | 41496 | 0.020 |
Why?
|
| Molecular Sequence Data | 4 | 1995 | 17598 | 0.020 |
Why?
|
| Cell Differentiation | 2 | 2001 | 11512 | 0.020 |
Why?
|
| Risk Assessment | 3 | 2011 | 24022 | 0.020 |
Why?
|
| Medicine | 1 | 2017 | 942 | 0.020 |
Why?
|
| Anemia, Sickle Cell | 1 | 1997 | 1063 | 0.020 |
Why?
|
| Filgrastim | 1 | 2009 | 132 | 0.020 |
Why?
|
| Schistosomiasis mansoni | 1 | 2009 | 94 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 1997 | 2137 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 2 | 2011 | 5493 | 0.020 |
Why?
|
| Interphase | 1 | 2008 | 227 | 0.020 |
Why?
|
| Professional Practice | 1 | 2010 | 313 | 0.020 |
Why?
|
| Decision Making | 1 | 2002 | 3931 | 0.020 |
Why?
|
| Thrombospondins | 1 | 2009 | 195 | 0.020 |
Why?
|
| Polyneuropathies | 1 | 2009 | 137 | 0.020 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 1991 | 790 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 3 | 1995 | 5773 | 0.020 |
Why?
|
| Drug Therapy, Combination | 2 | 2011 | 6304 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2018 | 4739 | 0.020 |
Why?
|
| Critical Illness | 1 | 2020 | 2724 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 2009 | 1140 | 0.020 |
Why?
|
| Mice | 4 | 2021 | 81330 | 0.020 |
Why?
|
| Partial Thromboplastin Time | 1 | 1988 | 204 | 0.020 |
Why?
|
| Echocardiography | 1 | 2020 | 5006 | 0.020 |
Why?
|
| Leukemia, Monocytic, Acute | 1 | 2006 | 58 | 0.020 |
Why?
|
| Karyotyping | 1 | 2008 | 1172 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 3 | 1987 | 1728 | 0.020 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2009 | 419 | 0.020 |
Why?
|
| Complementary Therapies | 1 | 2010 | 487 | 0.020 |
Why?
|
| Lipids | 1 | 2017 | 3331 | 0.020 |
Why?
|
| Crystallography, X-Ray | 1 | 2011 | 1978 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2009 | 1703 | 0.020 |
Why?
|
| Membrane Glycoproteins | 2 | 1994 | 3696 | 0.020 |
Why?
|
| Gene Expression Regulation | 2 | 1995 | 11855 | 0.020 |
Why?
|
| Critical Care | 1 | 1998 | 2696 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 12976 | 0.020 |
Why?
|
| Point Mutation | 1 | 2010 | 1593 | 0.020 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2010 | 2746 | 0.020 |
Why?
|
| Hypertension, Pulmonary | 1 | 2016 | 1592 | 0.020 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2006 | 263 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2009 | 1756 | 0.020 |
Why?
|
| Education, Medical, Continuing | 1 | 2010 | 825 | 0.020 |
Why?
|
| Enhancer Elements, Genetic | 1 | 1991 | 1360 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2011 | 2227 | 0.010 |
Why?
|
| Bleeding Time | 1 | 2004 | 83 | 0.010 |
Why?
|
| Observer Variation | 1 | 2010 | 2610 | 0.010 |
Why?
|
| Drug Utilization | 1 | 2010 | 1188 | 0.010 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2006 | 237 | 0.010 |
Why?
|
| Gastrointestinal Tract | 1 | 2009 | 834 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 14610 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1994 | 13402 | 0.010 |
Why?
|
| Nerve Block | 1 | 2010 | 706 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2011 | 3512 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2008 | 2509 | 0.010 |
Why?
|
| Papio | 1 | 2004 | 669 | 0.010 |
Why?
|
| Lung | 1 | 2020 | 9979 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2008 | 15521 | 0.010 |
Why?
|
| Hip Prosthesis | 1 | 1988 | 921 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 2005 | 1597 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2008 | 2658 | 0.010 |
Why?
|
| Food Industry | 1 | 2001 | 67 | 0.010 |
Why?
|
| Cysteine Endopeptidases | 1 | 2003 | 551 | 0.010 |
Why?
|
| Cold Temperature | 1 | 2004 | 783 | 0.010 |
Why?
|
| Pandemics | 1 | 2020 | 8663 | 0.010 |
Why?
|
| Lymphoma, B-Cell | 1 | 2006 | 938 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 2 | 2011 | 7407 | 0.010 |
Why?
|
| Incidence | 1 | 2017 | 21366 | 0.010 |
Why?
|
| HeLa Cells | 2 | 1976 | 3073 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2020 | 36415 | 0.010 |
Why?
|
| Calcium | 1 | 1991 | 5719 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 2009 | 3031 | 0.010 |
Why?
|
| Base Sequence | 3 | 1995 | 12404 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2010 | 3923 | 0.010 |
Why?
|
| Telephone | 1 | 2001 | 624 | 0.010 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 1997 | 178 | 0.010 |
Why?
|
| Carotid Artery Injuries | 1 | 1997 | 96 | 0.010 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2003 | 1318 | 0.010 |
Why?
|
| Carotid Artery, Common | 1 | 1997 | 175 | 0.010 |
Why?
|
| Dexamethasone | 1 | 2003 | 1945 | 0.010 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2006 | 1640 | 0.010 |
Why?
|
| Pediatrics | 1 | 2010 | 3590 | 0.010 |
Why?
|
| Cross Infection | 1 | 2003 | 1422 | 0.010 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1974 | 298 | 0.010 |
Why?
|
| Hyperplasia | 1 | 1997 | 1150 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2009 | 5301 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2012 | 22174 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2009 | 9417 | 0.010 |
Why?
|
| Growth Hormone | 1 | 1995 | 569 | 0.010 |
Why?
|
| United States Food and Drug Administration | 1 | 2001 | 1662 | 0.010 |
Why?
|
| Aspirin | 1 | 2004 | 3129 | 0.010 |
Why?
|
| Chick Embryo | 1 | 1974 | 977 | 0.010 |
Why?
|
| Sulfur Isotopes | 1 | 1971 | 21 | 0.010 |
Why?
|
| Galactosidases | 1 | 1971 | 55 | 0.010 |
Why?
|
| Dialysis | 1 | 1971 | 73 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1993 | 704 | 0.010 |
Why?
|
| Fructose-Bisphosphate Aldolase | 1 | 1971 | 43 | 0.010 |
Why?
|
| Data Collection | 1 | 2001 | 3320 | 0.010 |
Why?
|
| Transferases | 1 | 1971 | 71 | 0.010 |
Why?
|
| RNA Nucleotidyltransferases | 1 | 1971 | 58 | 0.010 |
Why?
|
| Electrophoresis | 1 | 1971 | 225 | 0.010 |
Why?
|
| Chromatography, Ion Exchange | 1 | 1971 | 294 | 0.010 |
Why?
|
| Ultracentrifugation | 1 | 1971 | 182 | 0.010 |
Why?
|
| Genes | 1 | 1995 | 1820 | 0.010 |
Why?
|
| Methods | 1 | 1971 | 1063 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 15920 | 0.010 |
Why?
|
| Chromatography, Gel | 1 | 1971 | 641 | 0.010 |
Why?
|
| Filtration | 1 | 1971 | 228 | 0.010 |
Why?
|
| Trypsin | 1 | 1971 | 486 | 0.010 |
Why?
|
| Cricetinae | 1 | 1974 | 2412 | 0.010 |
Why?
|
| Species Specificity | 1 | 1974 | 2406 | 0.010 |
Why?
|
| Plasmids | 1 | 1995 | 2261 | 0.010 |
Why?
|
| Urea | 1 | 1971 | 442 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 1974 | 1225 | 0.000 |
Why?
|
| Aspartic Acid | 1 | 1971 | 574 | 0.000 |
Why?
|
| Public Health | 1 | 2001 | 2672 | 0.000 |
Why?
|
| Body Mass Index | 1 | 2005 | 12952 | 0.000 |
Why?
|
| Immunosorbent Techniques | 1 | 1987 | 174 | 0.000 |
Why?
|
| Thrombophlebitis | 1 | 1988 | 289 | 0.000 |
Why?
|
| Chromosome Deletion | 1 | 1991 | 1386 | 0.000 |
Why?
|
| Organ Specificity | 1 | 1991 | 1963 | 0.000 |
Why?
|
| Rats, Inbred Strains | 1 | 1987 | 2087 | 0.000 |
Why?
|
| Tumor Cells, Cultured | 1 | 1993 | 6125 | 0.000 |
Why?
|
| Fibroblasts | 1 | 1995 | 4138 | 0.000 |
Why?
|
| Cytoplasmic Granules | 1 | 1987 | 573 | 0.000 |
Why?
|
| Polymers | 1 | 1971 | 1617 | 0.000 |
Why?
|
| Glycosaminoglycans | 1 | 1987 | 607 | 0.000 |
Why?
|
| Polymerase Chain Reaction | 1 | 1993 | 6067 | 0.000 |
Why?
|
| Microscopy, Electron | 1 | 1987 | 2561 | 0.000 |
Why?
|
| Cytoplasm | 1 | 1987 | 1498 | 0.000 |
Why?
|
| Cell Line | 1 | 1974 | 15545 | 0.000 |
Why?
|
| Kidney | 1 | 1974 | 7033 | 0.000 |
Why?
|
| Nuclear Proteins | 1 | 1993 | 5783 | 0.000 |
Why?
|
| DNA | 1 | 1991 | 7189 | 0.000 |
Why?
|
| DNA-Binding Proteins | 1 | 1993 | 9567 | 0.000 |
Why?
|